Peptide Health Lab

Longevity & cellular

FOXO4-DRI

FOR RESEARCH PURPOSES ONLY

Also known as: FOXO4 D-Retro-Inverso peptide, FOXO4-p53 interfering peptide

Regulatory status
Research only
Evidence grade
Animal studies only

Last reviewed September 1, 2026 · 14 sources

What FOXO4-DRI is and how it works

FOXO4-DRI is a synthetic 46-residue peptide with a molecular weight of about 5,358 daltons, built entirely from D-amino acids arranged in a reversed sequence. That construction is the "D-Retro-Inverso" in the name. The design logic, set out in the 2017 paper that created it, is that a protein interaction surface made of natural L-amino acids can sometimes be mimicked by a retro-reversed D-isoform, which resists the proteases that would degrade an ordinary peptide.[1] The molecule is two things joined together: a stretch copied from a region of the FOXO4 transcription factor that is conserved between humans and mice but differs from FOXO1 and FOXO3, and a polycationic cell-penetrating segment that carries the whole construct across cell membranes.[1]

The distinction that matters most on this page is between the peptide and its target. FOXO4 is a human transcription factor. FOXO4-DRI is a laboratory molecule designed to interfere with one thing that transcription factor does. Papers about FOXO4 biology are not papers about the peptide, and the two are routinely conflated in secondary writing about senescence.

The proposed mechanism is specific enough to be testable, which is unusual at this stage. Senescent cells are damaged cells that stop dividing but do not die, and they resist apoptosis. The origin study identified FOXO4 as the pivot of that resistance: in senescent cells FOXO4 accumulates in nuclear bodies and holds p53 there, keeping p53 from triggering the cell's own death programme.[1] The peptide competes for that interaction. In senescent cells this was reported to cause p53 to leave the nucleus and to activate caspase-3 and caspase-7, killing the cell from the inside.[1] A two-paragraph preview published alongside it in the same issue of Cell, under the heading "Rejuvenation by Therapeutic Elimination of Senescent Cells", restated that mechanism and framed the mouse results as rejuvenation — a framing that has since travelled a great deal further than the data behind it.[2] The wider FOXO4-p53 literature treats the axis as a genuine control point in cellular senescence while noting that many of the underlying molecular mechanisms remain unresolved.[3]

Later structural work supports the target rather than the therapy. Solution NMR models place the peptide on the disordered transactivation domain of p53, where it forms a transiently folded complex; both the FOXO4-derived region and the cationic permeability segment contribute to the binding, and phosphorylation of p53 increases the affinity.[11] Separate biophysical work maps two distinct binding surfaces between FOXO4 and p53, both with micromolar dissociation constants.[7] That is a well-characterized molecular interaction. It is not a clinical result.

What the research actually shows

In cultured human cells. The foundational experiments used senescent human IMR90 lung fibroblasts, with the selectivity comparison repeated in two further human fibroblast lines, BJ and WI-38. At a micromolar concentration in the culture medium, the peptide reduced viability in the senescent cells while the matched non-senescent cells were spared, and control IMR90 did not activate caspase-3.[1] Two independent groups have since reproduced selective senescent-cell removal in other human cell systems. In chondrocytes expanded in vitro to the point where they would be used for autologous implantation, treatment removed more than half the cells at the higher population-doubling level and reduced senescence markers — and, in the same study, did not improve the chondrogenic potential of those cells, which the authors reported plainly and which is the half of the result that usually goes missing.[5] In keloid organ cultures and keloid fibroblasts, the peptide promoted apoptosis with nuclear exclusion of phosphorylated p53.[10] Every one of these is human tissue in a dish. None of them is a person.

In mice. The origin study ran three separate in vivo models: chemotoxicity from doxorubicin, the fast-aging XpdTTD/TTD strain, and naturally aged animals of 110 weeks and older. The schedule was 5 mg per kilogram on three occasions, every other day — given intravenously in the chemotoxicity experiments, and intraperitoneally in the renal-function experiments in both aging cohorts, where the route was matched to the comparator those experiments were run against. The reported outcomes were neutralized chemotoxicity, recovered fitness, visibly improved fur density, and improved renal function measured by plasma urea and creatinine.[1] Healthspan measures, in mice; the study did not report a lifespan result.

Independent work has extended the pattern into specific tissues, though not always in the animal. One group used hydrogen-peroxide-senescent TM3 Leydig cells as an in-vitro model and reported there that the peptide selectively induced p53 nuclear exclusion and apoptosis in the senescent cells; the animal half of the same study reported that in naturally aged mice it improved the testicular microenvironment and relieved age-related testosterone-secretion insufficiency. The apoptosis result is the cell-culture half, and the testosterone result is the mouse half.[4] In naturally aged and progeroid mice, injection was reported to suppress aortic aging and improve aortic function; the mechanism the same authors propose — that blocking FOXO4 from binding p53 drives phosphorylated p53 out of the nucleus and triggers apoptosis — was worked out not in those animals but in cultured endothelial cells made senescent by oxygen-glucose deprivation, and the abstract does not say what species those cells came from.[12] In bleomycin-induced pulmonary fibrosis, treated animals showed milder pathological change and less collagen deposition.[9]

And a result that runs the other way. A 2023 study in Circulation investigated senescent cells in pulmonary hypertension using several clearance methods — a genetic suicide construct, the senolytic drug ABT263, and FOXO4-DRI. Mice overexpressing the serotonin transporter that were given either ABT263 or FOXO4-DRI showed pulmonary hemodynamic deterioration and loss of pulmonary endothelial cells relative to controls, and clearance by other methods produced higher right-ventricular systolic pressure and increased vessel remodelling. The authors concluded that eliminating senescent pulmonary endothelial cells may worsen pulmonary hemodynamics.[8] This is not a fringe finding in an obscure journal, and a page that reported only the favourable senolytic results would be misrepresenting the field.

Adjacent, and not the same molecule. A group at Oregon Health & Science University used molecular modelling to design a series of different peptides against the same FOXO4-TP53 interaction, characterized one of them, ES2, and reported that repeated systemic delivery reduced senescent cell numbers in the livers of older mice.[6] ES2 is not FOXO4-DRI. Results belonging to one do not transfer to the other.

Where the evidence is weak

No human being has been given this peptide in any published study. That is the single most important sentence on the page. There is no clinical trial, no case series, no case report, and therefore no human pharmacokinetics, no dose-finding, no adverse-event table, and no efficacy result of any kind. A 2026 review of FOXO4 as a therapeutic target states it directly: the peptide has shown senolytic activity in preclinical models but has not been clinically validated, and translation would require isoform- and tissue-specific validation, pharmacokinetic and delivery studies, long-term toxicology, and an explicit assessment of p53-dependent tumor surveillance.[14] None of that has been published.

"Human cells" is not "humans". Much of this compound's popular reputation rests on the fact that the cell-culture work uses human fibroblasts, chondrocytes and keloid tissue. A senescent human chondrocyte sitting in a well plate with a micromolar concentration of peptide around it is not a person with a joint.[5][10] The distance between those two situations is exactly the distance the field has not travelled.

Senolysis is a hypothesis, not an established good. The assumption underneath every consumer description of this peptide is that removing senescent cells improves the tissue they were in. In pulmonary hypertension models that assumption failed, with worse hemodynamics and loss of the endothelial cells that were being cleared.[8] In a different lung model it held.[9] One organ, two studies, opposite directions — which is what an unfinished question looks like.

Delivery is the gap between a dish and a body. A cell in culture is bathed in a known concentration. A cell in a person is behind a circulation, a clearance system, and a set of barriers, and a 46-residue polycationic peptide is not an obvious candidate for reaching all of them evenly. The structural work shows the cell-penetrating segment is not a passive carrier — it participates in the binding itself — which makes its behaviour in tissue a real question rather than a formality.[11]

The mechanism touches a tumor suppressor. Interfering with where p53 goes is not a casual intervention, and the same axis has been pursued deliberately as a way to kill senescent cancer cells.[6] The reviews that are most enthusiastic about the therapeutic idea still list tumor-surveillance assessment as undone.[14]

Commercial interest is disclosed in the primary literature. The structural paper carries declarations that the work was partly funded by a company developing senolytics, that two authors hold shares in it, and that several hold published patents covering compounds that inhibit the FOXO4-p53 interaction.[11] The disclosure is published and appropriate. It is also a reason to read the field's framing alongside its data.

Even the optimistic reviews run out of human evidence. A 2026 review arguing for retro-inverso senolytics in brain aging summarizes mouse results on cerebral blood flow, blood-brain-barrier integrity and memory, and when it reaches for human data it cites work on high-dose fisetin — a different agent entirely.[13] When a review advocating for a compound has to borrow another compound's human data, that is the state of the evidence.

Legal and regulatory status

FOXO4-DRI is not approved by the FDA for any indication. There is no approved application, no approved labeling, and no marketed product containing it under any name; verification against the FDA's approved-drug and approved labeling records returned nothing for this substance, while control queries run in the same session returned approved products as expected. It also does not appear on the FDA's published lists of bulk drug substances nominated for use in compounding under section 503A, in any of the three categories, so it has no recognized compounding position either. It is not a dietary supplement ingredient. Its only recognized identity in the United States is as a laboratory reagent — a research tool, catalogued as such, and that is the regulatory reality the research-only framing on this page reflects.

No regulator anywhere has approved it, and there is no publicly reported clinical development programme behind it; the review literature describes it as preclinical rather than as a candidate in trials.[14] Its status in tested sport is not separately documented in the published literature, and an athlete subject to testing should confirm the current position with their governing body rather than with a reference page.

PHL does not sell peptides and does not tell anyone where to obtain anything. What the regulatory position means for a reader is narrower and more useful than a firewall statement: there is no label, no approved manufacturer, no assigned indication, no established dose, and no regulated quality standard behind anything carrying this name.

Questions to bring to a provider

The useful version of this conversation is not "should I try FOXO4-DRI." It is "here is the age-related problem I actually have, what has evidence behind it, and where does a peptide that has never been given to a human being sit relative to that?" Questions worth raising:

  • The reviews list pharmacokinetics, long-term toxicology and tumor-surveillance work as prerequisites nobody has done. Which of those gaps would matter most for me specifically?[14]
  • What is known about how a peptide of this size and charge distributes in a human body, and what would be unknown about where it ended up?[11]
  • The mechanism works by changing where p53 sits inside a cell. What does a personal or family history of cancer mean for a question like that?[6]
  • One published study found that clearing senescent cells made pulmonary hemodynamics worse in mice. Does any existing cardiopulmonary history make that finding more relevant rather than less?[8]
  • If the underlying interest is joint pain, low testosterone, or vascular health, what does the standard-of-care evidence base offer for that specific problem, and how does it compare with a molecule at this stage?[4][5]
  • Senescent-cell burden is not something a routine panel reports. Is there any way to know whether a senolytic did what it is supposed to do, or would the whole exercise be unmeasurable?

A clinician who answers "there is no human study to reason from" is describing this literature accurately, not being unhelpful.

Evidence by claim

Grades describe how strong the evidence is; the line under each grade describes what kind of studies it is. How we grade evidence.

Selective killing of senescent cells in culture
Animal studies only animal · in vitro

The most reproducible result in the literature, and it is a cell-culture result. In senescent human IMR90 fibroblasts the peptide caused p53 nuclear exclusion and caspase-mediated apoptosis while control cells were spared. Independent groups have reproduced selective removal of senescent cells in in-vitro-expanded human chondrocytes and in keloid fibroblasts and keloid organ cultures. These are human cells in a dish, not people.

[1] [5] [10]

Restored fitness, fur density and renal function in aged mice
Animal studies only animal

In fast-aging XpdTTD/TTD mice and in naturally aged mice, the origin study reported recovered fitness, improved fur density, and improved renal function after three doses given every other day — intraperitoneal injection in the renal-function experiments in both cohorts — under conditions the authors described as well tolerated. These are healthspan measures in mice; the study did not report a lifespan result, and no equivalent experiment has been attempted in any other species.

[1]

Protection against chemotherapy-induced toxicity
Animal studies only animal

In mice given doxorubicin, the peptide was reported to neutralize chemotoxicity, with reduced markers of senescence and improved liver and renal readouts. This is a mouse model of a real clinical problem, which is what makes it interesting and also what makes the absence of any human follow-up notable nine years later.

[1]

Age-related testosterone decline and testicular function
Animal studies only animal

In hydrogen-peroxide-induced senescent TM3 Leydig cells and then in naturally aged mice, the peptide induced apoptosis in senescent Leydig cells and was reported to improve the testicular microenvironment and relieve age-related testosterone-secretion insufficiency. The authors frame this as therapeutic potential for male late-onset hypogonadism; it is a mouse result and has not been tested in men.

[4]

Vascular and endothelial aging
Animal studies only animal

In naturally aged and progeroid mice, treatment was reported to suppress aortic aging and improve aortic function, with the proposed route being nuclear exclusion of phosphorylated p53 in endothelial cells followed by apoptosis of the senescent ones. This sits alongside a published finding that removing senescent pulmonary endothelial cells worsened pulmonary hemodynamics in other mouse models, so the vascular picture is not one-directional.

[12] [8]

Engagement of the FOXO4-p53 interaction as the proposed mechanism
Animal studies only in vitro · review

The mechanistic case is unusually well developed for a compound at this stage. Solution NMR models show the peptide binding the disordered p53 transactivation domain and forming a transiently folded complex, with p53 phosphorylation increasing affinity; separate biophysical work maps two binding surfaces between FOXO4 and p53 with micromolar affinities. This is target engagement in purified systems and cells, which is mechanism rather than outcome.

[11] [7] [3]

Whether clearing senescent cells is beneficial
Animal studies only animal

Not settled, and the page would be dishonest without saying so. In a 2023 pulmonary-hypertension study, FOXO4-DRI itself was given in one model — mice overexpressing the serotonin transporter — and those animals showed pulmonary hemodynamic deterioration and loss of pulmonary endothelial cells; the deteriorations seen in the study's other models followed a p16-driven suicide gene or the senolytic drug ABT263 rather than the peptide, and the authors concluded that eliminating senescent pulmonary endothelial cells may worsen pulmonary hemodynamics. In a different lung model, bleomycin-induced pulmonary fibrosis, the same peptide reduced collagen deposition and pathological change. Two studies, one organ, opposite directions.

[8] [9]

Rejuvenation, healthspan, or any clinical effect in people
Anecdotal reports only review

No human efficacy evidence exists. No published trial, case series, or case report describes FOXO4-DRI being administered to a person for any purpose, so there is nothing to grade on its merits. A 2026 review of retro-inverso senolytics for brain aging reaches for human data and finds only studies of a different agent, high-dose fisetin, not the peptide; a second 2026 review states plainly that FOXO4-DRI has shown senolytic activity in preclinical models but has not been clinically validated.

[13] [14]

FOR RESEARCH PURPOSES ONLY

Typical protocol range in the research

  • Mice in the origin study — a doxorubicin chemotoxicity model, the fast-aging XpdTTD/TTD strain, and naturally aged animals of 110 weeks and older. The chemotoxicity experiments gave the peptide intravenously; the renal-function experiments in both aging cohorts gave it intraperitoneally, matching the route of the comparator they were run against. These figures are reported in the paper's figure legends and methods rather than in its PubMed abstract, so confirming them requires the full text and not the abstract record this citation resolves to

    5 mg per kilogram of mouse body weight, three doses on an every-other- day schedule (days 1, 3 and 5 as the chemotoxicity timeline sets it out), with fitness, fur density and renal endpoints read out up to 30 days after treatment [1]

  • Senescent human IMR90 lung fibroblasts in culture in the origin study, an in-vitro concentration rather than a systemic amount. Like the mouse schedule above, this concentration appears in the paper's methods and figure legends and not in its PubMed abstract

    25 µM added to the culture medium; the authors also compared a single exposure at the final concentration against three exposures at one third of it [1]

  • Humans, given FOXO4-DRI, for any purpose

    No published study has administered FOXO4-DRI to a person, so no human dose, schedule, or route is established; a 2026 review of FOXO4 as a therapeutic target states that the peptide has shown senolytic activity in preclinical models but has not been clinically validated [14]

The only real numbers in this literature are a mouse milligram-per-kilogram schedule and a micromolar concentration in a dish. Neither converts into an amount for a person: no pharmacokinetic study has measured what happens to this peptide in a human body, and a concentration that a cultured cell sits in is not a concentration a tissue reaches. Any figure circulating outside the published record has no source behind it and does not appear here.

Ranges are what published research reports, not a recommendation. PHL does not prescribe, and nothing here is personalized to you.

Side effects & safety signals

  • No human safety data of any kind

    Not established · Unknown, and that is an absence of evidence rather than a finding of safety. No published study has given this peptide to a person, so there is no adverse-event record, no dose-limiting toxicity, no pharmacokinetic description, and no long-term toxicology. A 2026 review of FOXO4 as a therapeutic target lists exactly those studies — pharmacokinetic and delivery work, long-term toxicology, and an explicit assessment of p53-dependent tumor surveillance — as prerequisites for clinical translation that have not been carried out.

    [14]

  • Senescent-cell clearance worsening pulmonary hemodynamics

    Reported in one mouse model of pulmonary hypertension · Serious as a mechanistic signal. In mice overexpressing the serotonin transporter, senolytic treatment including FOXO4-DRI was followed by pulmonary hemodynamic deterioration and loss of pulmonary endothelial cells, and the authors concluded that eliminating senescent pulmonary endothelial cells may worsen pulmonary hemodynamics. This is the clearest published reason not to treat senolysis as uniformly beneficial.

    [8]

  • Interference with p53, a tumor-suppressor pathway

    Not quantified in any safety study · A provider-discussion flag rather than a documented harm. The peptide works by moving where p53 goes inside a cell, and p53 is central to tumor surveillance. A 2026 review naming FOXO4-DRI states that clinical translation of FOXO4-p53 disruption requires explicit assessment of p53-dependent tumor surveillance, which has not been carried out. A separate group has pursued FOXO4-mimetic peptides specifically to kill senescent cancer cells, which is the same pathway approached from the opposite direction.

    [14] [6]

  • The cell-penetrating segment is not an inert carrier

    Described in structural work, not in a safety study · Uncharacterized in vivo. Solution NMR work found that both the FOXO4-derived region and the cationic cell-permeability segment contribute to binding the p53 transactivation domain, so the part of the molecule that gets it into cells participates in the interaction rather than simply delivering the rest. What a polycationic peptide of this size does across tissues over time in a person has not been studied.

    [11]

  • Selectivity established only against control cells and in mice

    Reported as selective in the systems tested · The origin work reported that the peptide reduced viability in senescent human fibroblasts while the matched non-senescent cells were spared, with that viability comparison run across three human fibroblast lines — IMR90, BJ and WI-38 — and described the in vivo conditions used as well tolerated. Selectivity against three cultured control cell lines and tolerability in mice over weeks are not the same thing as a human safety margin, and no study has looked for off-target effects in a person.

    [1]

  • Unverified identity and purity of unapproved material

    Not quantified · A category-level risk that sits on top of whatever the molecule itself does. With no approved manufacturer, nothing about the sequence fidelity, the D-amino-acid composition, the concentration, or the contaminant profile of material carrying this name is regulated or independently guaranteed. A 46-residue all-D peptide is also a demanding synthesis, so the gap between a label and its contents is not a theoretical one.

    [14]

Published lists are never exhaustive, so report anything unexpected to a licensed provider.

Storage, handling & reconstitution

Lyophilized storage
The originating laboratory described holding the lyophilized peptide at −20 °C in single-use one-milligram powder aliquots, specifically to avoid freeze-thaw artefacts, which is a laboratory-reagent handling convention rather than a shelf-life specification. No published stability study establishes how long the powder remains intact under any other condition, and there is no manufacturer specification to fall back on.
Reconstituted storage
Peptides in solution are conventionally kept refrigerated at 2–8 °C, protected from light, and treated as short-dated rather than indefinitely stable. Nothing in the FOXO4-DRI literature reports a solution shelf life, and the published experiments prepared solutions for immediate laboratory use rather than for storage.
Reconstitution diluent
Bacteriostatic water is the conventional diluent for lyophilized research peptides. It is worth noting that the published FOXO4-DRI experiments did not use it: the origin study dissolved the peptide in phosphate-buffered saline for both its cell-culture and its animal work, which is a laboratory preparation rather than anything intended for a person.
Reconstitution & handling
Conventional handling: sanitize the stopper before piercing it, add the diluent slowly down the inside wall rather than directly onto the powder, and let the powder dissolve on its own. Swirl gently if needed; never shake. A properly reconstituted solution is clear, and anything cloudy, discolored, or carrying visible particulate is discarded. PHL does not publish volume or unit calculations, because those are dosing decisions and dosing decisions belong with a licensed clinician.
Handling notes
FOXO4-DRI has no approved manufacturer, no label, no assigned beyond-use date, and no lot-level stability testing behind any storage claim. Everything above is either a description of what one laboratory did or a general convention, and neither is a specification.

The how-to guides cover the conventions behind these fields, and what the published stability data does and does not establish: Storage, Reconstitution, Handling.

Questions for your provider

Bring this page to a licensed provider. A provider can order labs, review your medications and history, and tell you whether anything here is relevant to your situation. This page can't. Peptide Health Lab does not prescribe and does not sell peptides.

Want a structured starting point for that conversation? The Stack Builder turns your goals into a research-cited outline you can review together.

Citations

14 sources · every identifier checked against PubMed

Before you act on any of this

This page is educational only and is not medical advice. It does not diagnose, treat, or prescribe. Review it with a licensed provider before making any health decision. Peptide Health Lab does not sell peptides.

How we grade and verify evidence · Terms of Use · Privacy Policy

Open the Stack Builder